 |
ARCHIVE # 4: 554 ARTICLES (NOV -SEPT 2006) |
|
|||||
My Educational Video on MS and MS Trials| Visitors Since 03/2006 |
||||||||||||||||||||||||||||||||||||||||
| Click here to read messages from our MySpace Friends HERE'S A FEW OF OUR 1,404 MySpace FRIENDS |
||||||||||||||||||||||||||||||||||||||||
 |
||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
 Click to view 1280 MS Walk photos! | ||||||||||||||||||||||||||||||||||||||||
| "Join a trial at Barrow & receive all medication & study based procedures at no charge!" | ||||||||||||||||||||||||||||||||||||||||
Stan Swartz, CEO, The MD Health Channel "WE PRODUCED THE FOLLOWING 9 VIDEOS FOR YOU!" Simply click the "video" buttons below: . |
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
| Previious Posts | ||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
| MS NEWS ARCHIVES: by week | ||||||||||||||||||||||||||||||||||||||||
| September 2006 | ||||||||||||||||||||||||||||||||||||||||
| October 2006 | ||||||||||||||||||||||||||||||||||||||||
| November 2006 | ||||||||||||||||||||||||||||||||||||||||
| July 2013 | ||||||||||||||||||||||||||||||||||||||||
| April 2014 | ||||||||||||||||||||||||||||||||||||||||
Monday, November 20, 2006
"Drug combo fuels hope for MS: Patients in small study showed shocking reversal of symptoms" - MSNBC.com
LONDON - Four years ago, 28-year-old multiple sclerosis patient Karen Ayres was wheelchair-bound and paralyzed. "I was trapped in a body that wouldn't do anything," she says. Now, following an experimental drug treatment, she has regained mobility and is studying for a doctoral degree.
Ayres was one of 27 patients with aggressive MS who was treated in an open trial with a course of cancer-drug mitoxantrone and copaxone, which is used to treat relapsing MS.
Like Ayres, many of the other patients in the study experienced results so remarkable that some MS experts, while expressing caution, are now taking a second look at the preliminary experiment.
A three-year controlled study is being launched at 10 centers across the United Kingdom to further investigate the potential of the drug combination. The results of the initial trial, led by Dr. Mike Boggild at the Walton Centre in Liverpool, will be published next month in the Journal of Neurology.
Mitoxantrone is an anti-cancer drug so powerful that it is potentially toxic and can only be used safely in the short term. So, Boggild and his colleagues combined its use with copaxone — a notoriously slow-acting drug.
"We decided to overlap the treatments because we wanted to give some time to copaxone to build up its effect," says Boggild.
What happened next was dramatic. "Patients who were just the worst of the worst did remarkably well," Boggild said.
"We think we've tapped into an unexpected synergy between the two drugs that gives you more than the sum of the parts," he says. With a few exceptions, Boggild says most of the patients treated with the drug combination are now essentially "trouble-free."
Though one patient developed acute leukemia — a known side effect to mitoxantrone treatment — Boggild says the majority of patients haven't had disease relapses.MORE: "Drug combo fuels hope for MS: Patients in small study showed shocking reversal of symptoms" - MSNBC.com
LONDON - Four years ago, 28-year-old multiple sclerosis patient Karen Ayres was wheelchair-bound and paralyzed. "I was trapped in a body that wouldn't do anything," she says. Now, following an experimental drug treatment, she has regained mobility and is studying for a doctoral degree.
Ayres was one of 27 patients with aggressive MS who was treated in an open trial with a course of cancer-drug mitoxantrone and copaxone, which is used to treat relapsing MS.
Like Ayres, many of the other patients in the study experienced results so remarkable that some MS experts, while expressing caution, are now taking a second look at the preliminary experiment.
A three-year controlled study is being launched at 10 centers across the United Kingdom to further investigate the potential of the drug combination. The results of the initial trial, led by Dr. Mike Boggild at the Walton Centre in Liverpool, will be published next month in the Journal of Neurology.
Mitoxantrone is an anti-cancer drug so powerful that it is potentially toxic and can only be used safely in the short term. So, Boggild and his colleagues combined its use with copaxone — a notoriously slow-acting drug.
"We decided to overlap the treatments because we wanted to give some time to copaxone to build up its effect," says Boggild.
What happened next was dramatic. "Patients who were just the worst of the worst did remarkably well," Boggild said.
"We think we've tapped into an unexpected synergy between the two drugs that gives you more than the sum of the parts," he says. With a few exceptions, Boggild says most of the patients treated with the drug combination are now essentially "trouble-free."
Though one patient developed acute leukemia — a known side effect to mitoxantrone treatment — Boggild says the majority of patients haven't had disease relapses.MORE: "Drug combo fuels hope for MS: Patients in small study showed shocking reversal of symptoms" - MSNBC.com